Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
Conditions: Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.
Conditions: Gastric Cancer Interventions: Drug: Tislelizumab; Drug: SOX/XELOX Sponsors: Xiangdong Cheng; Liaoning Tumor Hospital& Institute; Shanxi Province Cancer Hospital; Sichuan Cancer Hospital and Research Institute; The Second Affiliated Hospital of Harbin Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies
Conditions: Cancer, Ovarian; Chemotherapy Effect; Calorie Deficiency; Fasting, Intermittent Interventions: Other: Fasting Mimicking Diet; Drug: Chemotherapy Sponsors: L-Nutra Inc; University of Tennessee Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.
Conditions: Advanced Gastric Cancer; Neoadjuvant Therapy; Multi-omics Analysis Interventions: Procedure: combination chemotherapy with Apatinib or Camrelizumab Sponsors: Fujian Medical University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients
Conditions: Breast Cancer Interventions: Drug: cyclophosphamide , methotrexate , vinorelbine ,capecitabine Sponsors: Sun Yat-sen University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics
Conditions: Muscle-invasive Bladder Cancer Interventions: Other: neoadjuvant chemotherapy followed by radical cystectomy Sponsors: Yonsei University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Prognostic Factors for Survival in Patients With Cholangiocarcinoma
Conditions: Cholangiocarcinoma Interventions: Procedure: Resection/Ablation of tumor; Procedure: Palliative chemotherapy; Procedure: Neoadjuvant chemotherapy; Procedure: Stereotatic radiotherapy; Procedure: Best supportive care Sponsors: Rigshospitalet, Denmark Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
The Prediction Model of NAC Response for Breast Cancer Based on The Parametric Dynamics Features.
Conditions: Breast Cancer; Chemotherapy Effect; Diffusion Weighted MRI; PET Imaging; Multiparametric Magnetic Resonance Imaging Interventions: Radiation: Whole body 18F-FDG Positron Emission Tomography Sponsors: National Taiwan University Hospital; Ministry of Science and Technology, Taiwan Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Comparative Study on the Efficacy and Safety of Ondansetron Oral Membrane for the Prevention of Vomiting During Moderate Hypoemetic Chemotherapy
Conditions: To Analyze and Compare the Efficacy and Safety of Ondansetron and Tablet for the Prevention of Moderate and Hypoemetic Chemotherapy Interventions: Drug: Ondansetron oral membrane Sponsors: Shanghai Children ' s Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)
Conditions: SCLC, Limited Stage Interventions: Drug: Durvalumab; Drug: Chemotherapy drug of EP regimen; Radiation: radiotherapy Sponsors: Hebei Medical University Fourth Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab
Conditions: Early Breast Cancer; Triple Negative Breast Cancer Interventions: Drug: Pembrolizumab injection Sponsors: Fundacao Champalimaud Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC
Conditions: Intrahepatic Cholangiocarcinoma Interventions: Radiation: Radiotherapy; Drug: HAIC (GEMOX); Drug: Chemotherapy Sponsors: Shandong Cancer Hospital and Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib
Conditions: Non-small Cell Lung Cancer Interventions: Drug: Trilaciclib Sponsors: Henan Cancer Hospital; Jiangsu Simcere Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Chemotherapy Followed by Response-Based Reduced Radiation Therapy for Patients With Central Nervous System Germinomas
Conditions: Intracranial Germ Cell Tumor; Childhood Central Nervous System Germinoma Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Drug: Carboplatin; Drug: Etoposide; Radiation: Intensity-Modulated Radiation Therapy Sponsors: Children ' s Oncology Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer
Conditions: Triple-negative Breast Cancer; Cadonilimab Interventions: Drug: Cadonilimab Sponsors: Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
